PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MLTX vs. MMYT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MLTX and MMYT is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

MLTX vs. MMYT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MoonLake Immunotherapeutics (MLTX) and MakeMyTrip Limited (MMYT). The values are adjusted to include any dividend payments, if applicable.

-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2025February
-15.41%
1.64%
MLTX
MMYT

Key characteristics

Sharpe Ratio

MLTX:

-0.58

MMYT:

1.28

Sortino Ratio

MLTX:

-0.61

MMYT:

1.86

Omega Ratio

MLTX:

0.93

MMYT:

1.24

Calmar Ratio

MLTX:

-0.75

MMYT:

3.24

Martin Ratio

MLTX:

-1.57

MMYT:

8.35

Ulcer Index

MLTX:

18.93%

MMYT:

8.22%

Daily Std Dev

MLTX:

50.38%

MMYT:

53.39%

Max Drawdown

MLTX:

-64.60%

MMYT:

-73.45%

Current Drawdown

MLTX:

-34.07%

MMYT:

-15.62%

Fundamentals

Market Cap

MLTX:

$2.64B

MMYT:

$11.44B

EPS

MLTX:

-$1.27

MMYT:

$1.91

Total Revenue (TTM)

MLTX:

$19.74K

MMYT:

$935.76M

Gross Profit (TTM)

MLTX:

-$50.93K

MMYT:

$529.49M

EBITDA (TTM)

MLTX:

-$93.43M

MMYT:

$177.60M

Returns By Period

In the year-to-date period, MLTX achieves a -22.25% return, which is significantly lower than MMYT's -9.48% return.


MLTX

YTD

-22.25%

1M

-8.12%

6M

-13.36%

1Y

-21.38%

5Y*

N/A

10Y*

N/A

MMYT

YTD

-9.48%

1M

2.06%

6M

3.96%

1Y

77.07%

5Y*

29.34%

10Y*

15.37%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MLTX vs. MMYT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MLTX
The Risk-Adjusted Performance Rank of MLTX is 1313
Overall Rank
The Sharpe Ratio Rank of MLTX is 1616
Sharpe Ratio Rank
The Sortino Ratio Rank of MLTX is 1818
Sortino Ratio Rank
The Omega Ratio Rank of MLTX is 2020
Omega Ratio Rank
The Calmar Ratio Rank of MLTX is 77
Calmar Ratio Rank
The Martin Ratio Rank of MLTX is 44
Martin Ratio Rank

MMYT
The Risk-Adjusted Performance Rank of MMYT is 8484
Overall Rank
The Sharpe Ratio Rank of MMYT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of MMYT is 7777
Sortino Ratio Rank
The Omega Ratio Rank of MMYT is 7676
Omega Ratio Rank
The Calmar Ratio Rank of MMYT is 9595
Calmar Ratio Rank
The Martin Ratio Rank of MMYT is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MLTX vs. MMYT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and MakeMyTrip Limited (MMYT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MLTX, currently valued at -0.58, compared to the broader market-2.000.002.00-0.581.28
The chart of Sortino ratio for MLTX, currently valued at -0.61, compared to the broader market-4.00-2.000.002.004.006.00-0.611.86
The chart of Omega ratio for MLTX, currently valued at 0.93, compared to the broader market0.501.001.502.000.931.24
The chart of Calmar ratio for MLTX, currently valued at -0.75, compared to the broader market0.002.004.006.00-0.753.24
The chart of Martin ratio for MLTX, currently valued at -1.57, compared to the broader market-10.000.0010.0020.0030.00-1.578.35
MLTX
MMYT

The current MLTX Sharpe Ratio is -0.58, which is lower than the MMYT Sharpe Ratio of 1.28. The chart below compares the historical Sharpe Ratios of MLTX and MMYT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.00SeptemberOctoberNovemberDecember2025February
-0.58
1.28
MLTX
MMYT

Dividends

MLTX vs. MMYT - Dividend Comparison

Neither MLTX nor MMYT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

MLTX vs. MMYT - Drawdown Comparison

The maximum MLTX drawdown since its inception was -64.60%, smaller than the maximum MMYT drawdown of -73.45%. Use the drawdown chart below to compare losses from any high point for MLTX and MMYT. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-34.07%
-15.62%
MLTX
MMYT

Volatility

MLTX vs. MMYT - Volatility Comparison

The current volatility for MoonLake Immunotherapeutics (MLTX) is 11.83%, while MakeMyTrip Limited (MMYT) has a volatility of 15.13%. This indicates that MLTX experiences smaller price fluctuations and is considered to be less risky than MMYT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%12.00%14.00%16.00%18.00%20.00%22.00%SeptemberOctoberNovemberDecember2025February
11.83%
15.13%
MLTX
MMYT

Financials

MLTX vs. MMYT - Financials Comparison

This section allows you to compare key financial metrics between MoonLake Immunotherapeutics and MakeMyTrip Limited. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab